Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Cytosorbents (CTSO) Net Income towards Common Stockholders (2016 - 2025)

Cytosorbents' Net Income towards Common Stockholders history spans 15 years, with the latest figure at -$5.5 million for Q4 2025.

  • Quarterly results put Net Income towards Common Stockholders at -$5.5 million for Q4 2025, up 27.36% from a year ago — trailing twelve months through Dec 2025 was -$8.2 million (up 60.94% YoY), and the annual figure for FY2025 was -$8.2 million, up 60.43%.
  • Net Income towards Common Stockholders for Q4 2025 was -$5.5 million at Cytosorbents, down from -$3.2 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $1.9 million in Q2 2025 to a low of -$12.2 million in Q3 2022.
  • The 5-year median for Net Income towards Common Stockholders is -$6.0 million (2023), against an average of -$5.8 million.
  • The sharpest move saw Net Income towards Common Stockholders plummeted 1273.27% in 2021, then surged 145.34% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$9.3 million in 2021, then soared by 91.77% to -$766128.0 in 2022, then tumbled by 661.61% to -$5.8 million in 2023, then dropped by 29.69% to -$7.6 million in 2024, then rose by 27.36% to -$5.5 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at -$5.5 million, -$3.2 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.